Literature DB >> 23411094

Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force.

Benicio N Frey1, Ana C Andreazza, Josselin Houenou, Stéphane Jamain, Benjamin I Goldstein, Mark A Frye, Marion Leboyer, Michael Berk, Gin S Malhi, Carlos Lopez-Jaramillo, Valerie H Taylor, Seetal Dodd, Sophia Frangou, Geoffrey B Hall, Brisa S Fernandes, Marcia Kauer-Sant'Anna, Lakshmi N Yatham, Flavio Kapczinski, L Trevor Young.   

Abstract

Although the etiology of bipolar disorder remains uncertain, multiple studies examining neuroimaging, peripheral markers and genetics have provided important insights into the pathophysiologic processes underlying bipolar disorder. Neuroimaging studies have consistently demonstrated loss of gray matter, as well as altered activation of subcortical, anterior temporal and ventral prefrontal regions in response to emotional stimuli in bipolar disorder. Genetics studies have identified several potential candidate genes associated with increased risk for developing bipolar disorder that involve circadian rhythm, neuronal development and calcium metabolism. Notably, several groups have found decreased levels of neurotrophic factors and increased pro-inflammatory cytokines and oxidative stress markers. Together these findings provide the background for the identification of potential biomarkers for vulnerability, disease expression and to help understand the course of illness and treatment response. In other areas of medicine, validated biomarkers now inform clinical decision-making. Although the findings reviewed herein hold promise, further research involving large collaborative studies is needed to validate these potential biomarkers prior to employing them for clinical purposes. Therefore, in this positional paper from the ISBD-BIONET (biomarkers network from the International Society for Bipolar Disorders), we will discuss our view of biomarkers for these three areas: neuroimaging, peripheral measurements and genetics; and conclude the paper with our position for the next steps in the search for biomarkers for bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23411094     DOI: 10.1177/0004867413478217

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  65 in total

1.  Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications.

Authors:  B S Fernandes; J Steiner; M Berk; M L Molendijk; A Gonzalez-Pinto; C W Turck; P Nardin; C-A Gonçalves
Journal:  Mol Psychiatry       Date:  2014-09-30       Impact factor: 15.992

Review 2.  Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence.

Authors:  Anne Duffy
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

Review 3.  The role of DNA methylation in the pathophysiology and treatment of bipolar disorder.

Authors:  Gabriel R Fries; Qiongzhen Li; Blake McAlpin; Theo Rein; Consuelo Walss-Bass; Jair C Soares; Joao Quevedo
Journal:  Neurosci Biobehav Rev       Date:  2016-06-18       Impact factor: 8.989

Review 4.  Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites.

Authors:  George Anderson; Michael Maes
Journal:  Curr Psychiatry Rep       Date:  2015-02       Impact factor: 5.285

5.  GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs.

Authors:  Ana Isabelle G Queiroz; Maíra Moraes de Araújo; Tatiane da Silva Araújo; Greicy Coelho de Souza; Lígia Menezes Cavalcante; Michel de Jesus Souza Machado; David Freitas de Lucena; João Quevedo; Danielle Macêdo
Journal:  Metab Brain Dis       Date:  2015-06-16       Impact factor: 3.584

Review 6.  Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder.

Authors:  Cynthia V Calkin
Journal:  Ann Med       Date:  2019-08-27       Impact factor: 4.709

7.  Distinct lithium-induced gene expression effects in lymphoblastoid cell lines from patients with bipolar disorder.

Authors:  Gabriel R Fries; Gabriela D Colpo; Nancy Monroy-Jaramillo; Junfei Zhao; Zhongming Zhao; Jodi G Arnold; Charles L Bowden; Consuelo Walss-Bass
Journal:  Eur Neuropsychopharmacol       Date:  2017-09-20       Impact factor: 4.600

8.  A Glutamate Transporter EAAT1 Gene Variant Influences Amygdala Functional Connectivity in Bipolar Disorder.

Authors:  Sara Poletti; Martina Riberto; Benedetta Vai; Davide Ghiglino; Cristina Lorenzi; Alice Vitali; Silvia Brioschi; Clara Locatelli; Alessandro Serretti; Cristina Colombo; Francesco Benedetti
Journal:  J Mol Neurosci       Date:  2018-08-02       Impact factor: 3.444

9.  Anterior cingulate cortex choline levels in female adolescents with unipolar versus bipolar depression: a potential new tool for diagnosis.

Authors:  Xian-Feng Shi; Lauren N Forrest; M Danielle Kuykendall; Andrew P Prescot; Young-Hoon Sung; Rebekah S Huber; Tracy L Hellem; Eun-Kee Jeong; Perry F Renshaw; Douglas G Kondo
Journal:  J Affect Disord       Date:  2014-06-02       Impact factor: 4.839

Review 10.  Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells.

Authors:  Bradley Watmuff; Shaunna S Berkovitch; Joanne H Huang; Jonathan Iaconelli; Steven Toffel; Rakesh Karmacharya
Journal:  Mol Cell Neurosci       Date:  2016-01-14       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.